Conference Track

Metabolic Complications and Adverse Events

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Increased Markers of Inflammation and Coagulation and Greater Mortality Risk in SMART Study
Markers of Cardiac Dysfunction Observed With Increasing HIV-1 RNA During Treatment Interruption on HAART
Elevated Death Rates Demonstrated in HIV-Infected Patients With CD4+ Cell Counts > 350 cells/mm³
Maraviroc Therapy Associated With Lesser Increases in Lipid Levels vs Efavirenz in Treatment-Naive Patients
Low-Dose Ritonavir Associated With Decreases in HDL Cholesterol and Increases in Triglycerides Among Healthy Volunteers
Both Antiretroviral and Nonantiretroviral Factors Associated With Lipoatrophy and Reductions in Limb Fat in ACTG 5142
SWEET Study: Switch to Tenofovir/Emtricitabine From Zidovudine/Lamivudine Associated With Recovery of Limb Fat
HIV Infection Associated With Subclincal Atherosclerosis Through Factors Independent of HAART, Viral Replication
Reductions in Increased Markers of Endothelial Activation Observed After HAART Initiation
Untreated HIV Infection Associated With Increased Endothelial Activation, Inflammation Compared With Treated, Stable Patients and HIV-Uninfected Controls
D:A:D: Recent Use of Abacavir and Didanosine, but Not Thymidine Analogues, Associated With Risk of Myocardial Infarction
Similar Loss of Bone Mineral Density at Week 96 in Treatment-Naive Patients on Either Efavirenz- or Lopinavir/Ritonavir-Based Therapy
Behavioral Risk Factors Contribute to Cardiac Abnormalities in Current HIV Treatment Era
Cardiac Abnormalities More Common in HIV-Infected Asymptomatic Adults vs HIV-Negative Controls

Expert Analysis

Clinical Update on Metabolic Complications and Adverse Events

Faculty:

Andrew Carr, MBBS, MD, FRACP
Judith S. Currier, MD, MSc
William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify new findings on factors associated with increased risk of mortality in HIV-infected populations
Discuss new data on risks of and treatment for body habitus changes
Identify new findings on NRTI-associated increased risk of myocardial infarction

CREDIT INFORMATION

Release Date: April 04, 2008

Expiration Date: April 03, 2009

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Registered Nurses: 0.7 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.